Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

NCT00330733 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

71

Enrollment

FED

Sponsor class

Conditions

Atherosclerosis
Cardiovascular Disease
Inflammation
Insulin Resistance
Noninsulin-dependent Diabetes Mellitus

Interventions

DRUG: Salsalate
DRUG: Placebo

Sponsor

VA Office of Research and Development

Collaborators

[object Object]